What Are CAR-T Cells?

CAR-T cells are genetically engineered autologous T lymphocytes that express a synthetic receptor (chimeric antigen receptor) combining:

1. Extracellular domain: Single-chain variable fragment (scFv) — antibody-like structure recognizing tumor antigen
2. Transmembrane domain: Bridges cell surface to intracellular
3. Intracellular signaling domains:
   • CD3ζ (primary): T-cell receptor signaling
   • Costimulatory domains: CD28 or 4-1BB (second signal for T-cell activation)

Generation: 1. Autologous T-cell collection (leukapheresis) 2. Ex vivo transduction with CAR construct (viral or non-viral) 3. Ex vivo expansion (2–4 weeks in cell therapy facility) 4. Single infusion into patient

Selected CAR-T Products

Selected examples: CD19-directed products include tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, and lisocabtagene maraleucel. BCMA-directed products include idecabtagene vicleucel and ciltacabtagene autoleucel. They differ in construct, indicated disease, eligibility, and toxicity profile. This is not an exhaustive current approval list; verify the exact product label and cell-therapy protocol. PubMed 40107382

CAR-T Kinetics & Renal Relevance

Cell expansion, CRS, ICANS, and AKI may overlap after infusion. Their onset and duration vary by product, disease burden, prior treatment, and patient factors. A calendar day alone cannot exclude a complication. Follow the product-specific monitoring schedule and investigate new fever, hypotension, hypoxia, neurologic change, or reduced urine output promptly.

Definition & Pathophysiology [1]

CRS is a systemic inflammatory response caused by massive CAR-T proliferation and consequent immune activation.

Cytokine cascade:

CAR-T cells recognize antigen on tumor/normal B-cells
    ↓
T-cell receptor + CD28/4-1BB signaling → T-cell activation
    ↓
CAR-T secretion of:
├─ IL-2, IL-7 (T-cell growth factors)
├─ IL-6 (pro-inflammatory; acts on IL-6R)
├─ TNF-α, IFN-γ (macrophage activation)
├─ GM-CSF (hematopoietic cell activation)
└─ Other: MCP-1, IP-10, IL-10
    ↓
Activation of:
├─ Macrophages → more IL-6, TNF-α
├─ Endothelial cells → loss of barrier function
├─ Mast cells, neutrophils → further cytokine release
└─ Systemic inflammatory cascade
    ↓
SYSTEMIC CONSEQUENCES:

CRS Grading: ASTCT Consensus

Use the ASTCT consensus rather than mixing historical systems. CRS begins with fever ≥38°C not attributable to another cause; the grade is determined by the more severe hypotension or hypoxia criterion. Once antipyretic or anti-cytokine treatment has been given for CRS, fever is no longer required for subsequent grading.

Assess alternative causes of shock and hypoxia, especially infection. Kidney injury is documented and staged separately; creatinine or dialysis does not independently set the ASTCT CRS grade. PubMed 30592986

Mechanisms of CRS-Related AKI [1]

Clinical Presentation of CRS-Related AKI [1]

Trend creatinine and urine output alongside fever, blood pressure, oxygen needs, examination, and fluid balance. A rising creatinine or oliguria warrants prompt evaluation even outside an expected post-infusion window. Obtain cultures and assess infection when appropriate; CRS and sepsis can coexist. Cohort frequencies describe their enrolled populations, not a universal incidence for all products. PubMed 31973908

Definition & Incidence

ICANS is a distinct neurologic toxicity that may occur with or after CRS. Assess and grade it with the ASTCT framework, including the ICE assessment in suitable adults, consciousness, seizures, motor findings, and cerebral edema. Symptoms such as new aphasia, altered handwriting, confusion, or seizure require urgent cell-therapy and neurologic assessment. PubMed 30592986

Renal Involvement in ICANS

Kidney failure, sodium disorders, drug accumulation, and infection can mimic or aggravate encephalopathy. Do not attribute every neurologic change to ICANS. Cerebral edema requires specialist management; neither routine fluid restriction nor aggressive fluid loading is a universal answer. Maintain appropriate perfusion while avoiding overload and rapid osmotic shifts. Prolonged seizures can cause rhabdomyolysis and pigment-associated tubular injury.

Hypophosphatemia & Phosphate Wasting

Hypophosphatemia is common in some cohorts. Potential contributors include intracellular redistribution during cellular activation, poor intake, and renal losses; the mechanism may be multifactorial. B-cell aplasia is not evidence of loss of an FGF23-producing organ. Assess severity, symptoms, nutrition, kidney function, and concurrent potassium/calcium before oral or intravenous replacement, with serial reassessment. PubMed 31973908

Hypokalemia & Potassium Wasting

Consider gastrointestinal loss, poor intake, medications, renal wasting, and intracellular shifts. B-cell depletion is not a valid explanation based on “loss of potassium stores.” Check magnesium and ECG when indicated. Replace potassium according to severity, route feasibility, kidney function, and a monitored protocol.

Hypomagnesemia

Poor intake, gastrointestinal losses, and nephrotoxic or diuretic exposures can lower magnesium. Investigate contributing drugs and replace with monitoring; magnesium deficiency may impede correction of hypokalemia. Kidney failure changes replacement safety.

Hyponatremia: Establish the Mechanism

Confirm tonicity and assess volume status, urine osmolality, urine sodium, drugs, adrenal function, and recent fluids. Inflammatory or nausea-related antidiuresis is possible, but ICANS does not by itself establish SIAD. Severe neurologic symptoms with hypotonic hyponatremia require urgent monitored treatment and careful correction limits.

Baseline Workup

Document stable baseline creatinine and an appropriate eGFR estimate, urinalysis/proteinuria, sodium, potassium, bicarbonate, calcium, magnesium, phosphate, urate, and medication exposures. Evaluate blood pressure, fluid balance, cardiac disease, and prior AKI. Creatinine-based eGFR is unreliable while kidney function is changing rapidly. The 2021 CKD-EPI equation is an estimating equation, not a “KDIGO 2021 formula.”

Pre-CAR-T Optimization

Eligibility is individualized with the cell-therapy team; a single eGFR threshold does not define candidacy for every product. Correct reversible hypovolemia or electrolyte deficits and review medication doses, interactions, and avoidable nephrotoxins. Fludarabine-containing lymphodepletion requires particular attention to kidney function and exposure. Temporarily holding RAAS therapy depends on hypotension, AKI, potassium, and indication rather than a label of universal nephrotoxicity. PubMed 37010812

Post-Infusion Monitoring

Follow the product and center protocol, with more frequent assessment for CRS, TLS risk, AKI, unstable electrolytes, or neurologic change. Track vital signs, fluid intake/output, weight, creatinine, electrolytes, magnesium, and phosphate. Add urate, LDH, and other TLS studies when indicated. Monitoring continues after discharge according to risk; a fixed days 0–14 schedule is not sufficient for every patient.

Renal Function Monitoring Details

Apply standard AKI criteria using the creatinine trajectory and urine output, while examining possible causes. A percentage change in creatinine alone is not a dialysis trigger. Review hypotension, sepsis, congestion, TLS, obstruction, and drugs; use urinalysis and imaging as appropriate. Adjust drug dosing as kidney function evolves.

CRS Grade 1–2 (Mild-Moderate)

Assess fever and instability urgently, including infection evaluation and indicated empiric antimicrobial treatment. Provide supportive care and use the product-specific CRS treatment algorithm. Tocilizumab may be indicated before grade 3; do not wait for severe shock when the protocol calls for earlier intervention. Choose fluid boluses and reassessment according to perfusion and overload risk, not a fixed urine-output target.

CRS Grade 3–4 (Severe) with AKI [1]

CRS symptoms: High fever, hypotension requiring vasopressors, hypoxia requiring supplemental O2/intubation

Renal status: Cr >3× baseline OR eGFR <30 OR oliguria (<500 mL/day) OR dialysis requirement

Management:

CAR-T in Pre-Existing CKD

Baseline CKD reduces physiologic reserve and affects lymphodepleting-drug dosing, fluid tolerance, and monitoring. Coordinate oncology, nephrology, pharmacy, and critical care. CKD alone does not establish a universal exclusion threshold, a nonexistent “grade 2.5 CRS,” or an automatic earlier dialysis threshold. PubMed 37010812

CAR-T in Dialysis Patients

Published experience demonstrates feasibility in selected dialysis patients, but evidence is limited and treatment requires individualized planning. Coordinate lymphodepletion dosing, drug dialyzability, dialysis timing, volume, and electrolyte management with the cell-therapy team. Do not routinely omit dialysis on infusion day or promise outcomes equivalent to patients without kidney failure. PubMed 37010812

CAR-T in Cardiac Dysfunction

Baseline cardiac dysfunction increases the complexity of CRS-related shock and congestion. Establish an individualized cardiac assessment and monitoring plan, with cardiology input when indicated. Treat perfusion deficits and excess fluid according to repeated clinical assessment; neither universal fluid restriction nor routine fluid loading is appropriate.

Post-CAR-T Kidney Recovery

Recovery varies with cohort, injury severity, and associated organ dysfunction. In a 46-patient retrospective lymphoma series, no patient required dialysis and most AKI recovered toward baseline within 30 days. That finding should not be generalized to severe ICU-associated AKI or converted into an individual recovery probability. PubMed 32088364

Chronic Renal Function Post-CAR-T

Persistent kidney dysfunction occurs after severe illness. A retrospective ICU cohort found substantial CKD among a small number of AKI survivors with available follow-up; it does not establish an all-recipient incidence. Reassess kidney recovery after discharge and evaluate for new or worsened CKD, with earlier follow-up for persistent AKI or dialysis. PubMed 38915438